Table 1.

Effects of kindling and PB treatment on distribution of PB in plasma, cerebral cortex and hippocampus

	PTZ-PB		PB-CT
	14 day treatment	40 day treatment	14 day treatment	40 day treatment
Plasma, µg·mL−1	72.19 ± 6.98	77.04 ± 5.16	64.84 ± 11.04	66.50 ± 16.52
Cortex, µg·g−1 tissue	23.44 ± 3.58	20.53 ± 3.19	23.45 ± 4.89	16.74 ± 5.00*
Cortex/plasma, mL·g−1	0.32 ± 0.06	0.27 ± 0.04*	0.36 ± 0.04	0.25 ± 0.04**
Hippocampus, µg·g−1 tissue	52.26 ± 9.57	35.93 ± 5.56**	32.06 ± 5.59	26.21 ± 5.12*
Hippocampus/plasma, mL·g−1	0.72 ± 0.11	0.47 ± 0.08**	0.50 ± 0.06	0.39 ± 0.10*

The treated kindled rats (PTZ-PB rats) and age-matched treated rats (PB-CT rats) were orally given PB (45 mg·kg⁻¹·day⁻¹, i.g.) for consecutive 14 or 40 days. At 1 h after PB administration (i.g.), PB concentrations in plasma, cerebral cortex, and hippocampus were measured. Each value is presented as mean ± SD (n= 8).

^*P < 0.05,

^**P < 0.01 versus the 14th day using Student's t-test.

PB, phenobarbital; PTZ, pentylenetetrazole.